Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Octagam / Panzyga (immunoglobulin portfolio) by Year
Octagam / Panzyga (immunoglobulin portfolio) — Worldwide revenues ($M) ($M)
Pfizer Octagam / Panzyga (immunoglobulin portfolio): $418M in FY2025, down 17.9% from a year earlier.
Where the FY2025 figure comes from
“|| Octagam | 418 | 509 | (18%) | (18%) | 418 | 509 | (18%) | — | — | — | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Octagam / Panzyga (immunoglobulin portfolio) — Worldwide revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 418 | -17.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 509 | +107.8% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 245 | -50.1% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 491 | +14.2% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 430 | +14.4% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 376 | – | Form 10-K (filed 2023-02-23) ↗ |
Breakdown
What makes up octagam / Panzyga (immunoglobulin portfolio)
Cite this data
StockData. (2026). Pfizer Octagam / Panzyga (immunoglobulin portfolio) ($M), annual FY2020–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/octagam-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.